1. Home
  2. FCNCP vs SCLXW Comparison

FCNCP vs SCLXW Comparison

Compare FCNCP & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FCNCP
  • SCLXW
  • Stock Information
  • Founded
  • FCNCP N/A
  • SCLXW N/A
  • Country
  • FCNCP United States
  • SCLXW United States
  • Employees
  • FCNCP 17475
  • SCLXW 111
  • Industry
  • FCNCP Major Banks
  • SCLXW Biotechnology: Pharmaceutical Preparations
  • Sector
  • FCNCP Finance
  • SCLXW Health Care
  • Exchange
  • FCNCP Nasdaq
  • SCLXW Nasdaq
  • Market Cap
  • FCNCP N/A
  • SCLXW N/A
  • IPO Year
  • FCNCP N/A
  • SCLXW N/A
  • Fundamental
  • Price
  • FCNCP $21.70
  • SCLXW $0.33
  • Analyst Decision
  • FCNCP
  • SCLXW
  • Analyst Count
  • FCNCP 0
  • SCLXW 0
  • Target Price
  • FCNCP N/A
  • SCLXW N/A
  • AVG Volume (30 Days)
  • FCNCP N/A
  • SCLXW 4.0K
  • Earning Date
  • FCNCP N/A
  • SCLXW 03-07-2025
  • Dividend Yield
  • FCNCP N/A
  • SCLXW N/A
  • EPS Growth
  • FCNCP N/A
  • SCLXW N/A
  • EPS
  • FCNCP N/A
  • SCLXW N/A
  • Revenue
  • FCNCP N/A
  • SCLXW $55,152,000.00
  • Revenue This Year
  • FCNCP N/A
  • SCLXW N/A
  • Revenue Next Year
  • FCNCP N/A
  • SCLXW N/A
  • P/E Ratio
  • FCNCP N/A
  • SCLXW N/A
  • Revenue Growth
  • FCNCP N/A
  • SCLXW 22.02
  • 52 Week Low
  • FCNCP N/A
  • SCLXW $0.18
  • 52 Week High
  • FCNCP N/A
  • SCLXW $0.18
  • Technical
  • Relative Strength Index (RSI)
  • FCNCP 46.71
  • SCLXW N/A
  • Support Level
  • FCNCP $21.56
  • SCLXW N/A
  • Resistance Level
  • FCNCP $21.94
  • SCLXW N/A
  • Average True Range (ATR)
  • FCNCP 0.30
  • SCLXW 0.00
  • MACD
  • FCNCP -0.06
  • SCLXW 0.00
  • Stochastic Oscillator
  • FCNCP 43.75
  • SCLXW 0.00

About FCNCP First Citizens BancShares Inc.

First Citizens BancShares Inc is the bank holding company of First Citizens Bank and Trust Company. The company's segments include the General Bank, the Commercial Bank, SVB Commercial, and Rail. The General Bank segment delivers products and services to consumers and businesses through its extensive network of branches and various digital channels. The Commercial Bank segment provides financial services, including lending, leasing, and advisory, to small and mid-market businesses across various industries. The SVB Commercial provides financial services to innovators, investors, and venture firms. The Rail segment provides tailored leasing and financing for railcars and locomotives across North America. It generates the majority of its revenue from the General Banking segment.

About SCLXW Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Share on Social Networks: